| AIM: SNG | |
| Industry | Drug discovery Biotechnology |
| Founded | 2003[1] |
| Founder | |
| Headquarters | , |
Key people |
|
| Website | synairgen |
Synairgen is a University spin-off and public limited company (plc) [2][1][3] working in drug discovery and biotechnology. It was founded in 2003 by University of Southampton professors Stephen Holgate,[4] Donna E. Davies and Ratko Djukanovic. The company is developing an inhaled formulation of interferon-beta for severe viral respiratory diseases including COVID-19.[5][6][7][8][9]
Richard Marsden was appointed chief executive officer in September 2009.[10]
- ^ a b Anon (2016). "SYNAIRGEN PLC". companieshouse.gov.uk. London: Companies House.
- ^ Anon (2020). "SYNAIRGEN PLC SNG Stock". londonstockexchange.com. London Stock Exchange.
- ^ Rowlatt, Justin (July 20, 2020). "Covid treatment trial described as 'breakthrough'". bbc.co.uk. BBC News.
- ^ "Clean Air Champion Professor Sir Stephen Holgate receives Knighthood". Clean Air Programme. 2021-12-07. Retrieved 2022-02-03.
- ^ "- Synairgen". synairgen.com. Retrieved 2022-02-03.
- ^ Neate, Rupert (July 24, 2020). "'Major' breakthrough in Covid-19 drug makes UK professors millionaires". The Guardian.
- ^ Anon (2020). "Expert reaction to announcement by Synairgen that their drug SNG001 has had positive results in initial trials on COVID-19 patients". Science Media Centre.
- ^ Donnelly, Laura (July 20, 2020). "Coronavirus drug hailed as game-changer after trial finds it cuts chances of severe illness". telegraph.co.uk. Daily Telegraph.
- ^ Holgate, Stephen; Agusti, Alvar; Strieter, Robert M.; Anderson, Gary P.; Fogel, Robert; Bel, Elisabeth; Martin, Thomas R.; Reiss, Theodore F. (2015). "Drug development for airway diseases: looking forward". Nature Reviews Drug Discovery. 14 (6): 367–368. doi:10.1038/nrd4645. ISSN 1474-1776. PMID 26000726. S2CID 8539798.
- ^ "SNG: Synairgen PLC Stock Price Quote - London - Bloomberg". bloomberg.com. Retrieved 2022-02-03.